Md. Code, Health Occupations § 12-504.1
This is the official text of Md. Code, Health Occupations § 12-504.1, part of Maryland’s Code, Health Occupations — governs the licensing of healthcare professionals.
Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.
§12–504.
Official statutory text
§12–504.1.
(a) Except as provided in subsection (d) of this section, within 5 business days after dispensing a biological product to a patient, the dispensing pharmacist or the pharmacist’s designee shall communicate the specific biological product dispensed, including the name and manufacturer of the biological product, to the prescriber.
(b) Except as provided in subsection (c) of this section:
(1) The communication required under subsection (a) of this section shall be provided by making an entry that is electronically accessible to the prescriber through:
(i) An interoperable electronic medical records system;
(ii) An electronic prescribing technology;
(iii) A pharmacy benefits management system; or
(iv) A pharmacy record; and
(2) Making an entry through a mechanism listed in paragraph (1) of this subsection is presumed to provide the communication to the prescriber required under subsection (a) of this section.
(c) If the mechanisms listed in subsection (b)(1) of this section are not available, the communication required under subsection (a) of this section may be provided by facsimile, telephone, electronic transmission, or other means.
(d) The communication requirement under subsection (a) of this section does not apply if:
(1) The United States Food and Drug Administration has not approved an interchangeable biological product for the biological product prescribed to the patient; or
(2) A refill prescription is not changed from the biological product dispensed on the most recent filling of the prescription.
(a) Except as provided in subsection (d) of this section, within 5 business days after dispensing a biological product to a patient, the dispensing pharmacist or the pharmacist’s designee shall communicate the specific biological product dispensed, including the name and manufacturer of the biological product, to the prescriber.
(b) Except as provided in subsection (c) of this section:
(1) The communication required under subsection (a) of this section shall be provided by making an entry that is electronically accessible to the prescriber through:
(i) An interoperable electronic medical records system;
(ii) An electronic prescribing technology;
(iii) A pharmacy benefits management system; or
(iv) A pharmacy record; and
(2) Making an entry through a mechanism listed in paragraph (1) of this subsection is presumed to provide the communication to the prescriber required under subsection (a) of this section.
(c) If the mechanisms listed in subsection (b)(1) of this section are not available, the communication required under subsection (a) of this section may be provided by facsimile, telephone, electronic transmission, or other means.
(d) The communication requirement under subsection (a) of this section does not apply if:
(1) The United States Food and Drug Administration has not approved an interchangeable biological product for the biological product prescribed to the patient; or
(2) A refill prescription is not changed from the biological product dispensed on the most recent filling of the prescription.
Status: in_force · Read it on the official government site
Need a lawyer in Maryland?
Find a Maryland lawyer
About this page: Statute text is reproduced from official government publishers via the
Open US Law dataset
(Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine
(Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.